Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.

[1]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Knapp,et al.  Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125. , 1990 .

[3]  A. D. Van den Abbeele,et al.  Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. , 1989, American journal of obstetrics and gynecology.

[4]  P. Saigo,et al.  Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  V. Zurawski,et al.  Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. , 1989, Gynecologic oncology.

[6]  R. W. Baldwin,et al.  Intraperitoneal 131I- and 111In‐791T/36 monoclonal antibody in recurrent ovarian cancer: imaging and biodistribution , 1989, Nuclear medicine communications.

[7]  A. Herbst,et al.  The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. , 1989, American journal of obstetrics and gynecology.

[8]  D. Snook,et al.  Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. , 1989, International journal of radiation oncology, biology, physics.

[9]  R. Dale,et al.  Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. , 1988, British Journal of Cancer.

[10]  H. Haisma,et al.  Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors. , 1988, American journal of obstetrics and gynecology.

[11]  R. Knapp,et al.  Localization of radiolabelled F(ab′)2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts , 1988, International journal of cancer.

[12]  A. Martinez,et al.  Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P W Doherty,et al.  Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  W. Hawkins,et al.  Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. , 1988, International journal of radiation oncology, biology, physics.

[15]  H. Haisma,et al.  An assay for the detection of human anti-murine immunoglobulins in the presence of CA125 antigen. , 1988, Journal of immunological methods.

[16]  Edwin Silverberg,et al.  Cancer statistics, 1988 , 1988, CA: a cancer journal for clinicians.

[17]  R. Dillman,et al.  Toxicities associated with monoclonal antibody infusions in cancer patients. , 1988, Molecular biotherapy.

[18]  V. Zurawski,et al.  Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  V. Ernster,et al.  Progesterone and breast cancer. , 1986, Obstetrics and gynecology.

[20]  T. Krausz,et al.  Antibody‐guided irradiation of malignant ascites in ovarian cancer: A new therapeutic method possessing specificity against cancer cells , 1986, Obstetrics and gynecology.

[21]  R. Dillman,et al.  Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. , 1986, Journal of biological response modifiers.

[22]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[23]  R. Dillman,et al.  Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Mirzadeh,et al.  211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. , 1984, International journal of radiation oncology, biology, physics.

[25]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[26]  R. Bast,et al.  Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[27]  L. Burnett,et al.  Radioactive Phosphorus and External Radiation as an Adjuvant to Surgery for Ovarian Carcinoma , 1978, Obstetrics and gynecology.

[28]  J. Woodruff,et al.  Biologic Behavior of Primary Ovarian Malignancy , 1974, Obstetrics and gynecology.